compani lly-
invest summari modest ep miss maintain ow rate
increas month pt pt increas pt
driven upward earn revis sale growth margin expans pipelin
advanc off-set competit older product view
therefor think upward earn revis drive share higher
takeaway support posit thesi report strong
full year result repres yoy ep growth
respect exclud fx oper margin improv yoy
expect lower ep guidanc reflect pend acquisit
loxo lartruvo setback still expect achiev
sale oper margin goal despit loxo lartruvo adjust
guidanc revenu grew driven
olumi jardianc verzenio lartruvo repres sale
 driven diabet product deliv
volum growth plan launch exchang offer sharehold
would tender share exchang elanco
cover share order divest remain ownership interest elanco
exact time decis launch offer depend upon market
condit offer could begin earli come day
exchang offer complet restat guidanc reflect elanco
discontinu oper interest oncolog immunolog
two area
report adjust dilut ep factset
consensu line estim decreas ep guidanc
first present invest commun meet
factset consensu factset estim
updat acquisit loxo lartruvo set back may
earn releas date move recent said
updat estim averag revis model
result outlook increas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
greater expect brand and/or gener competit lilli key drugs/product
number lilli top-sel human pharmaceut product recent lost
lose next sever year signific patent protect and/or data protect
well key countri outsid certain signific product longer
effect exclus patent protect data protect non-biolog product
loss exclus whether expir consequ litig typic result
entri one gener competitor lead rapid sever declin
revenu especi histor outsid market penetr gener
follow loss exclus rapid pervas howev gener
market penetr increas mani market outsid includ japan europ
mani countri emerg market biolog humalog humulin erbitux
cyramza trulic taltz loss exclus may may result near-term entri
competitor version biosimilar due develop timelin manufactur challeng
and/or uncertainti regulatori pathway approv competitor version
setback lilli pipelin could headwind compani futur growth prospect
lilli compet larg number multi-national pharmaceut compani biotechnolog
compani gener pharmaceut compani compet success lilli must
continu deliv market innov cost-effect product meet import medic
lilli human pharmaceut busi subject increas govern price control
public privat restrict price reimburs access drug
could materi advers effect busi public privat payer take
increasingli aggress step control expenditur human pharmaceut
place restrict price reimburs patient access lilli medic
pressur could neg affect futur revenu net incom lilli expect
price reimburs access pressur govern privat payer insid
outsid becom sever
manufactur difficulti disrupt could lead product suppli problem
anim health manufactur complex highli regul
manufactur difficulti lilli facil contract facil failur refus
contract manufactur suppli contract quantiti could result product shortag
lead lost revenu difficulti disrupt could result qualiti regulatori
complianc problem natur disast mechan inform technolog system failur
inabl obtain sole-sourc raw intermedi materi addit given difficulti
predict sale new product long lead time necessari expans
regulatori qualif pharmaceut manufactur capac possibl lilli
could difficulti meet unanticip demand new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
amount chang yoyamount chang yoyvariancecommentstot increas volum newer pharmaceut product trulic taltz basaglar gross increas expens relat newer pharmaceut product launch launch oper non oper pre-tax tax adjust net averag adjust dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom phase enrol alzheim linagliptin phase top-lin data carolina cv outcom studyend abemaciclib phase trial phase long-term efficaci safeti top-line readout oa pain studi top-line readout clbp studi dulaglutid regulatori submiss rewind top-line readout crohn ixekizumab phase top-line data non-radiograph axial data phase exchang offer divest remain ownership interestjun dulaglutid present detail rewind result ada scientif ramucirumab merestinib data pivot phase trial biliari tract canceraugust exclus europ full data top-line on-going ad phase baricitinib phase initi psoriat baricitinib phase initi alopecia agonist initi phase studi initi crohn pegyl phase renal cell antibodyphas readout identifi biomark key kinas inhibitorphas posit alloster modul pam phase readout parkinson diseas glucagonregulatori decis /eu top-line data congest heart failur chf exercis abil ixekizumab regulatori submiss radiograph axial spondyloarthr ixekizumab regulatori action radiograph axial ixekizumab phase top-line data psoriasi head-to-head vs tremfya guselkumab ramucirumab phase top-lin relay data egfr nsclc ramucirumab regulatori action high afp hepatocellular cancer lisprodata present medic meet type type galcanezumab eu regulatori submiss episod cluster galcanezumab approv episod cluster studi public scientif meet data releas psoriat premetrex patent litig ipr appeal outcom studybegin enrol empagliflozin regulatori submiss type empagliflozin approv type empagliflozin result empris agonist present full titrat studi data help manag gi side effect medic approv acut lisproregulatori submiss /eu/japan type type diabetessourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom studi overcom avail baselin dulaglutid phase top-line data altern dose type phase emperial-preserv outcom trial chronic phase emperial-reduc outcom trial chronic readout solid abemaciclib keytrudaphas data hr breast cancer kra nsclc non-squam kinase/mtor dual inhibitor prostat penregulatori submiss type type diabet ret inhibitor phase data nsclc thyroid cancer late pegyl pembrolizumab cypress nsclc top-line resultsl pegyl nivolumab io nave cypress nsclc top-line resultsl ret inhibitor submiss nsclc thyroid readout cancer baricitinib phase top-line data alopecia lispropotenti overal surviv os top-line data agonist initi surpass cvot event driven power cv dulaglutid label updat rewind phase emperor hf-preserv outcom trial chronic phase emperor hf-reduc outcom trial chronic phase empa-kidney outcom trial chronic kidney readout alzheim readout dian pegyl folfoxphas sequoia pancreat cancer top-line readout solid abemaciclib result phase adjuv studi hr breast cancer baricitinib phase top-line data system lupu antibodyphas readout alzheim top-line data ulcer agonist phase surpass data type diabet vs glargin establish pegyl insulin deliveri systempotenti outcom studymain studi premetrex eu loss premetrex japan loss submissionl agonist complet phase surpass program type empagliflozin phase estimate primari complet date chronic kidney diseas agonist potenti global studi overcom end data premetrex patent expir loss pediatr exclus abemaciclib nce exclus readout aspirinu patent dulaglutid patent agonist data surpass cvot event driven power cv patent patent jentaduet patent ramucirumab patent ixekizumab patent abemaciclib patent baricitinib eu patent baricitinib patent ixekizumab eu loss baricitinib japan patent galcanezumab patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
eli mm except per share amount pharma margin revenu sell incom revenu rate per share outlookmin sale compound-annual-growth-rate constant currenc full sale compound-annual-growth-rate constant currenc human oper margin revenu excl fx human cantor fitzgerald research compani reportsnot financi guidanc tabl expect gross margin revenu tax rate ep guidanc assum elanco minor interest entireti loxo oncolog acquisit close fx assumpt yen renminbi individu element financi guidanc includ fulli consolid financi expect human pharma andelanco health busi except ep exclud non-control interest plan launch exchang offer sharehold order divest remain ownership interest elanco exchang offer complet restat financi guidanc reflect elanco discontinu oper exact time exchang offer depend market prior earn non- ep guidanc updat guidanc reflect updat expect lartruvo partial off-set inclus vitrakvi posit trend core busi perform addit loxo oncolog develop portfolio increas net interest expens loxo acquisit financ adjust tax reform previous announc expect neg impact non- lartruvo updat non- guidanc reflect impact anticip loxo oncolog revenu growth expect driven volum newer medicin trulic taltz basaglar jardianc verzenio cyramza olumi recent launch emgal anticip inclus vitrakvi could benefit potenti approv launch medicin revenu growth expect partial off-set lower revenu ciali product lost patent exclus neg impact foreign exchang rate continu price pressur includ higher rebat medicar part intern market impact neg lartruvo phase incom expens guidanc updat reflect addit interest expens associ financ pend acquisitoin loxo expect pharma includ non- gross margin ms income/ expens non- tax rate oper incom project mid-singl digit declin price off-set increas volum expect increas pharma contribut part donut hole reduc revenu nearli start februari emgal best-in-class cgrp term access coverag three largest payer number tailwind jardianc updat ada easd guidelin place emphasi prefer jardianc within thisclass reinclus formulari increas invest competitor class acceler double-digit growth jardianc run thelow- nrx believ long-term continu see better gross margin better sg sale compani grow top-lin intern income-basedr expect stay toward top industri see good opportun today function compani growth strategi choic ishard specul direct go exhibit incom statement analysi
million compound-annual-growth-rate year end decemb oper expens oper net dilut changetot oper expens incom nmnmnmnmnmnmnmnmnmnmnmnmoper net dilut cantor fitzgerald research compani report exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat agreement astrazeneca co-develop charg relat impact venezuelan financi crisi includ signific deterior bolivar integr sever cost relat acquisit novarti anim health global sever cost asset impair relat closur anim health manufactur facil ireland exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat busi develop activ primarili driven acquisit colucid pharmaceut inventori step-up cost associ acquisit boehring ingelheim vetmedica felin canin rabi vaccin portfolio charg primarili associ effort reduc compani cost structur includ voluntari earli retir program charg relat recent enact tax reform legisl includ one-tim repatri transit tax also known toll tax exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat busi develop activ co ltd inc hydra bioscienc charg primarili associ sever cost incur result action taken reduc compani cost structur well expens associ separ elanco anim health busi adjust tax reform tax expens associ separ elanco anim health busi exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb product intern pipelin product anim health changeu product intern anim health cantor fitzgerald research compani report cardio includ zalutia livalo endocrinolog includ acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ ceclor keflex licens fee incom jardianc revenu includ glyxambi synjardi trajenta revenu includ jentadueto biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version exhibit annual sale analysi
 product intern launch pipeline/newli launch product anim health cantor fitzgerald research compani report cardio includ zalutia livalo endocrinolog includ acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ ceclor keflex licens fee incom jardianc revenu includ glyxambi synjardi trajenta revenu includ jentadueto biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version year end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas net proce sale acquisit net cash acquired- net cash use invest flow financ activ repay issuanc long term dividend net cash use provid financ effect exchange-r cash net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt current total current plant properti identifi total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling total liabil stockhold sourc cantor fitzgerald research compani report februari
engag discoveri develop manufactur sale pharmaceut product compani sell product world-wide
follow therapeut area neurosci endocrinolog oncolog cardiovascular
